HIGHLIGHTS
- What: The authors aimed to investigate the cost-effectiveness of tislelizumab plus chemotherapy compared to chemotherapy alone as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (OSCC). The study demonstrated that tislelizumab and chemotherapy combination may be a cost-effective treatment strategy considering the current state of Chinese economy. A cost-effectiveness analysis was conducted to compare different PD-1 inhibitors in combination with chemotherapy for the firstline treatment of advanced OSCC in China .
- Who: Chaoneng He and colleagues from the squamous cell carcinoma in China have published the Article: Cost . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.